Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial

EMC - Otorinolaringoiatria · Elsevier

Аннотация

Publication date: June 2026 Source: EJC Paediatric Oncology, Volume 7 Author(s): Britta Vormoor, Joshua Savage, Caroline Kristunas, Sarah Johnson, Mauricio Nicolás Ferrao Blanco, Geoff Shenton, Donna Lancaster, Anna Castleton, Adele K. Fielding, Anne-Louise Latif, Nick Morley, Marion Strullu, Ruta Tuckuviene, Pamela Kearns, Claire Jennings, Shelby Barnett, Gareth J. Veal, Julie Irving, Lucinda Billingham, Tobias Menne

Читать у издателя →

Похожие статьи